Notably, pan-cancer analysis showed that EPHB6 could not exert the similarly cold immune effects in most other types of cancer; hence, anti-EPHB6 immunotherapy might be suitable for patients with BLCA only, but it requires further clinical investigations. This evidence concerns the gene EPHB6 and bladder transitional cell carcinoma.